Seeking Innovative DMPK and Safety Research for Therapeutics and Drug Delivery Systems

Takeda Pharmaceutical are launching an open innovation initiative, inviting researchers to submit their ideas and technologies across five different focus areas, up to £60k / €70k / $100k (AUD). Summarised below are the interests of Takeda relating to DMPK and safety research for Therapeutics and Drug Delivery Systems. In the attached application form, each of these topics have been expanded upon to give further detail of proposals.

Submissions should be relevant to one or more of the following titles: 

• REF #24 Microphysiological blood-brain barrier (BBB) systems to evaluate drug delivery system (DDS) technologies for large molecules
• REF #25 Development of mass spectrometry imaging technology equipped with cellular resolution and high sensitivity enabling the pharmacokinetic evaluation of small/large molecules
• REF #26 Technology of ultra-sensitive assay for biomarkers and new drug modalities by mass spectrometry platform using novel assay pre‑treatment and/or detection systems
• REF #27 Development of Drug Safety Assessments with digital solutions
• REF #28 Development of the novel biomarkers or preclinical screening systems to predict drug-induced central nervous system side effects (cognitive impairment, hallucinations, suicidal ideation and drug dependence)
• REF #29 The discovery of safety biomarkers using bacteria
• REF #30 Development of next-generation in vitro organ model systems mimicking toxicokinetics for toxicity studies

Global Eligibility: 

Only submissions from Europe and Australia will be eligible for this campaign.

How to Apply: 

 To view more details on each area of interest seeking proposals for funding, download an application form here.To submit your proposal, please visit discover.in-part.com, register, and submit as a Research Project under the appropriate Discover campaign.